EDITORIAL GOVERNANCE & MEDICAL REVIEW
-
✓
Content Author: Ms. Hannah Matthews (B.Sc. - Biochemistry)
-
✓
Medically Reviewed By: Dr. N. Kumar, DM, Member of the International Society for Stem Cell Research (ISSCR).
-
✓
State Medical Council Registration No.: Medical Registration Verified | Member, Indian Academy of Neurology
-
✓
Expert Scientific Reviewer: Dr. Harinath P, PhD (Stem Cell Biology & Regenerative Immunology)
-
✓
Clinical Governance Protocol:
SOP-STR-02(Investigational Cellular Protocol)
Condition Context & Investigational Scope
Clinical classification, underlying pathophysiology, and biological cellular rationale in India
Clinical Classification & Regulatory Status:
Under national ICMR and National Medical Commission (NMC) directives, stem cell therapy for ischemic and hemorrhagic stroke is strictly investigational and experimental. It is not recognized by the CDSCO as an approved routine commercial treatment and does not replace standard acute thrombolysis, mechanical thrombectomy, surgical hematoma evacuation, or daily neuro-rehabilitation.
Pathophysiology & Disease Context:
Stroke—whether caused by arterial occlusion (ischemic) or intracranial vascular rupture (hemorrhagic)—leads to primary neuronal cell death, penumbral ischemia, peri-hematomal inflammation, and persistent neurological deficits (hemiparesis, spasticity, dysphasia).
Biological Rationale & Paracrine Action:
Investigates targeted intravenous or intrathecal delivery of clinical-grade umbilical cord-derived mesenchymal stem cells (UC-MSCs) or autologous bone marrow mononuclear cells (BMMNCs). Therapy aims to modulate secondary neuro-inflammation, stimulate endogenous neurogenesis and angiogenesis (via BDNF, GDNF, VEGF paracrine secretion), and support synaptic plasticity along the ischemic penumbra.
Candidate Eligibility & Diagnostic Pre-Screening
Comprehensive inclusion markers, mandatory diagnostics, and safety exclusion parameters
Target Patient Profile:
Medically stable patients in the subacute or chronic phase ($>1\text{ to }3$ months post-stroke) exhibiting non-progressive motor deficits (hemiparesis, hemiplegia), spasticity, or speech deficits with fixed plateaus despite compliant conventional physical therapy.
Mandatory Pre-Procedure Diagnostics:
High-resolution Brain 3T MRI (including DWI, FLAIR, and SWI sequences to delineate infarct core and chronic hematoma resorption), carotid Doppler / CT Angiography, 2D Echocardiogram, baseline National Institutes of Health Stroke Scale (NIHSS), Modified Rankin Scale (mRS), and Barthel Index (BI) functional scores.
Strict Safety Exclusion Parameters:
Acute, unstable evolving stroke ($<1\text{ month}$ post-onset); active intracranial bleeding or expanding hematoma; severe unmanaged cerebral edema or midline shift; uncontrolled intracranial hypertension; high seizure frequency (refractory status epilepticus); or intracranial neoplasms.
Triage Protocol & Multi-Specialty Clearance:
Multidisciplinary case review by a vascular neurologist and neuro-intensivist before issuing travel clearance.
Potential Functional Goals & Documented Risks
Reported supportive clinical goals alongside complete procedural and biological risk transparency
Reported Functional Goals (Supportive & Variable):
- Motor Recovery & Ambulation: Modest improvements in upper/lower extremity strength (Fugl-Meyer Motor Assessment scores), gait stability, and assisted step cadence.
- Spasticity Modulation: Measurable reduction in hypertonia and muscle rigidity on the Modified Ashworth Scale (MAS).
- Fine Motor Dexterity: Subtle recovery in voluntary finger movement, grip power, and hand-to-mouth coordination.
- Speech & Swallowing: Improvement in post-stroke expressive aphasia and oral motor coordination for safer swallowing.
- Independence in Activities of Daily Living (ADLs): Incremental gains in functional autonomy reflected on the Barthel Index and Functional Independence Measure (FIM).
Documented Procedural Risks & Limits:
- Self-limiting post-infusion low-grade pyrexia, headache, lightheadedness, or injection-site discomfort resolving within 24–48 hours.
- Rare risks: transient hemodynamic fluctuations, mild meningismus following intrathecal delivery, or transient neurological worsening.
- No Guaranteed Restoration: Stem cells cannot resurrect dead, cystic, or fully encephalomalacic brain tissue; functional recovery depends heavily on neuroplasticity reinforced by continuous physical and occupational therapy.
Why Undergo Treatment at Our Medical Center in India?
World-class tertiary healthcare infrastructure, cGMP certified cleanrooms, and compassionate patient-centered care
Accredited Hospitals
Delivered exclusively in tertiary neuroscience hospitals accredited by NABH and JCI.
Dedicated Stroke Units
Supervised directly by stroke neurologists, neuro-intensivists, and certified neuro-rehabilitation therapists.
ISO/cGMP Laboratory Standards
Cell handling adheres strictly to international Good Manufacturing Practices and CDSCO safety parameters.
Institutional Ethics Oversight
Supervised by active Institutional Ethics Committees (IEC) registered with the Department of Health Research (DHR) and CDSCO.
Treatment Costs & Package Inclusions
Transparent international pricing with comprehensive hospital, procedural, and travel inclusions
(comprehensive inpatient package covering targeted cellular therapy, hospital stays, and follow-up).
(Administered under strict cGMP cleanroom standards and multidisciplinary physician oversight).
| Country / Region | Typical Package Range | Waiting Period | Clinical Accreditation |
|---|---|---|---|
| India (Our Partner Centers) | Starting from $4,000 USD | 1 – 2 Weeks | JCI / NABH Accredited |
| United States | $28,000 – $55,000 USD | 3 – 6 Months | Clinical Trial Gated |
| Germany & Switzerland | $25,000 – $48,000 USD | 2 – 4 Months | Private Specialty Only |
| Panama / Mexico | $18,000 – $35,000 USD | 2 – 4 Weeks | Variable Regional |
Dedicated Support for International Patients & Families
End-to-end medical concierge care ensuring a safe, stress-free international treatment journey
Pre-Arrival Video Consultation
Remote telemedicine conference with senior stroke neurologists to evaluate MRI brain scans, NIHSS scores, and establish realistic recovery expectations.
Government Medical Visa
Fast-track assistance with official Government of India Medical Visa (MED) and Medical Attendant (MED-X) invitation documentation.
Dedicated Case Liaison
Single multilingual point of contact coordinating airport transfers, hospital registration, specialized rehabilitation scheduling, and medical records.
Structured Remote Follow-Up
Scheduled virtual evaluations at Months 1, 3, 6, and 12, coordinating repeat motor scale tracking, mRS scores, and rehabilitation milestones with your home neurologist.
Travel, Accommodation & Local Logistics
Planning your medical journey to New Delhi, Mumbai, or Bangalore with complete peace of mind
Wheelchair-Accessible Transfers
Private, air-conditioned vehicle pick-up and drop-off equipped with wheelchair accessibility to ensure safe, low-fatigue transit.
Accessible Partner Accommodations
Partner 4-star and 5-star serviced apartments located within 10 minutes of the hospital, featuring wide doorways, step-free access, elevator facilities, and roll-in showers with grab rails.
Patient Amenities
Dysphagia-safe and neuro-supportive nutritional meal planning supervised by clinical dietitians, local SIM registration, wheelchair/walker loaners, and 24/7 on-call nursing support.
Clinical Protocol & In-Hospital Schedule
Structured clinical workflow during your stay in India (Stay Duration: 4 to 5 days structured in-hospital observation pathway.):
Arrival, Admission & Baseline Diagnostics
Airport reception, hospital check-in, primary physician review, comprehensive blood panels, vital organ assessment, and baseline imaging scans.
Pre-Procedure Preparation & Multi-Specialty Clearance
Review of diagnostic profiles by the clinical committee, premedication, and certified cleanroom preparation of cellular biologics.
Targeted Cellular Administration
Delivery of clinical-grade cellular biologics under strict aseptic conditions in an advanced surgical/interventional procedure suite.
Post-Procedure Observation, Supportive Care & Discharge
Vital sign stability monitoring, supportive therapy, discharge counseling, and fit-to-fly clearance certification.
Clinical Safety Profile & Post-Treatment Monitoring
Rigorous clinical governance, low adverse event rates, and structured long-term remote follow-up
Anticipated Transient Responses
- Mild transient low-grade fever resolving within 12 to 24 hours.
- Mild localized injection-site soreness or temporary tenderness.
- Transient procedural fatigue responsive to oral hydration and rest.
Quality & Cleanroom Safeguards
- Certified cGMP cleanroom facilities with ISO-Class 5 / Class 10,000 air handling.
- Flow cytometry viability testing (>90% cell viability confirmed).
- Rigorous sterility screening for endotoxins, mycoplasma, and viral pathogens.
Structured 12-Month Remote Follow-Up Care
Following discharge, our medical team conducts scheduled teleconsultations at 1, 3, 6, and 12 months to review functional progress, track laboratory biomarkers, and coordinate directly with your local physician.
Frequently Asked Questions
Evidence-based answers to key clinical, safety, cost, and travel inquiries regarding Ischemic & Hemorrhagic Stroke
Peer-Reviewed Clinical Trial References & Registry Citations
Published scientific trials, systematic reviews, and official registry citations validating cellular safety and therapeutic mechanisms
Landmark Multicenter Randomized Controlled Trial of Autologous Bone Marrow MSCs in Ischemic Stroke (STARTING-2)
Chung, J. W., Chang, W. H., Bang, O. Y., Moon, G. J., Kim, S. J., Kim, S. K., Lee, J. S., Sohn, S. I., Kim, D. E., & STARTING-2 Collaborators. (2021). Efficacy and Safety of Intravenous Mesenchymal Stem Cells for Ischemic Stroke: A Randomized, Double-Blind, Placebo-Controlled Trial (STARTING-2). Stroke, 52(4), 1142–1152.
First-in-Human Phase 1/2a Clinical Trial of Allogeneic Modified BM-MSCs in Chronic Stroke Deficits
Steinberg, G. K., Kondziolka, D., Wechsler, L. R., Lunsford, L. D., Coburn, M. L., Billigen, J. B., ... & Schwartz, N. E. (2016). Clinical Outcomes of Transplanted Modified Bone Marrow-Derived Mesenchymal Stem Cells in Stroke: A Phase 1/2a Study. Stroke, 47(7), 1817–1824.
Clinical Trial on Autologous Mesenchymal Stem Cells in Subacute Basal Ganglia Hemorrhagic Stroke
Tsang, K. S., Ng, H. K., Zhu, X. L., Wong, G. K., Lu, G., Ahuja, A. T., Wong, K. S., & Poon, W. S. (2017). Phase I/II Randomized Controlled Study of Autologous Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Chronic Motor Deficits from Intracerebral Hemorrhage. World Neurosurgery, 105, 512–521.
Systematic Review & Meta-Analysis of Mesenchymal Stem Cell Interventions in Clinical Stroke
Boncoraglio, G. B., Ranieri, M., Bersano, A., Parati, E. A., & Del Giovane, C. (2019). Stem cell transplantation for ischemic and hemorrhagic stroke: a systematic review and meta-analysis of clinical trials. Stem Cell Research & Therapy, 10(1), 283.
Statutory Notice & Mandatory Regulatory Disclosure:
In compliance with the National Guidelines for Stem Cell Research jointly formulated by the Indian Council of Medical Research (ICMR) and Department of Biotechnology (DBT), as well as directives from the National Medical Commission (NMC), stem cell and biological therapies for Ischemic and Hemorrhagic Stroke are classified as strictly investigational and experimental. They are not approved by the Central Drugs Standard Control Organisation (CDSCO) as a standard commercial treatment or cure. Cellular therapies do not replace emergency medical interventions or prescribed secondary stroke prevention medications (e.g., antiplatelets, anticoagulants, antihypertensives, and statins). Patients must continue their prescribed pharmacological treatments and active physical rehabilitation under specialist care.
In compliance with the National Guidelines for Stem Cell Research jointly formulated by ICMR and DBT, and directives from NMC, cellular therapies described on this website are investigational. Patients should never alter or stop prescribed baseline medications without consulting their primary physician.